• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

McConnell ’ s Bid to Downplay Freezes Undermined by History of Politicians Lying About Their Health
After Senate Minority Leader Mitch McConnell froze during a press conference this month, the Kentucky Republican’s second such episode this summer, his office released a note from the Capitol physician intended to calm those worried about his ability to continue at his job. Dr. Brian Monahan told McConnell in the letter that there was “no evidence that you have a seizure disorder or that you experienced a stroke, TIA or movement disorder such as Parkinson’s disease.” Monahan suggested the episodes may be related to the Leader’s concussion in March or to dehydration.  [time-brightcove n...
Source: TIME: Health - September 11, 2023 Category: Consumer Health News Authors: Mini Racker Tags: Uncategorized Congress Source Type: news

Pregnancy-Associated Takotsubo Cardiomyopathy Hospitalizations in the United States
Am J Physiol Heart Circ Physiol. 2023 Jul 7. doi: 10.1152/ajpheart.00262.2023. Online ahead of print.ABSTRACTTakotsubo cardiomyopathy (TCM) is most common in postmenopausal women aged ≥ 50 years but also affects pregnant individuals. However, there are no national estimates on the prevalence, timing of occurrence, correlates, and outcomes of Pregnancy-associated TCM. Using the Nationwide Inpatient Sample (NIS: 2016-2020), we describe rates of pregnancy-associated TCM hospitalizations among 13 - 49 years old pregnant individuals in the United States by selected demographic, behavioral, hospital, and clinical characteristi...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 7, 2023 Category: Physiology Authors: Mulubrhan F Mogos Soojung Ahn James M Muchira Sarah Osmundson Mariann R Piano Source Type: research

Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota. Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research

Current U.S. Guideline-Based Management Strategies for Special Clinical Situations Involving Hypertensive Crises: A Narrative Review of the Literature
Hypertensive crises, although somewhat rare in hypertensive patients, might become an increasingly relevant issue in the future as the number of adults living with hypertension in the United States increases. Many of the current U.S. clinical guidelines for the treatment and management of a variety of medical conditions do not factor hypertensive crises into their recommendations or only consider them in a limited fashion in the context of other medical conditions. This review article summarizes the definitions of hypertensive crises/urgent hypertension/emergent hypertension, the epidemiological profile and outcomes of pat...
Source: Cardiology in Review - December 9, 2021 Category: Cardiology Tags: Review Articles Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The Joint Association of Septicemia and Cerebrovascular Diseases with In-Hospital MortalityAmong Patients with Left Ventricular Assist Device in the United States
Currently, about 6.2 million adults in the US are reported to have heart failure, and this prevalence is expected to increase by 46% by 2030.1 The prognosis of advanced heart failure especially, advanced systolic heart failure, has improved tremendously with the advent of implantable mechanical circulatory support devices such as left ventricular assist device (LVAD) which is often used as a bridge to heart transplantation or as a destination therapy.2,3 Indeed, LVAD has improved the 1-year survival of patients with advanced heart disease from 52% to about 85%.
Source: Journal of Stroke and Cerebrovascular Diseases - January 19, 2021 Category: Neurology Authors: Jessica Lovelace, Obadeh Shabaneh, Noah De La Cruz, Damilola R. Owoade, Chike C. Nwabuo, Nandini Nair, Duke Appiah Source Type: research

Approaches in Prehospital Sepsis Screening
Discussion In the United States, sepsis is one of the leading causes of death, which requires timely identification and proper treatment (CDC, 2019; Guerra et al., 2020; Polito et al., 2015). Based upon a review of literature conducted from 2014 to 2018, the primary investigators could locate five prehospital EMS screening tools to assist EMS providers in identifying at-risk sepsis patients. The researchers explored how the modified SIRS and qSOFA scoring systems were used in hospital settings in addition to these five prehospital EMS screening tools. The Bas 90-30-90, Guerra, PRESEP, PRESS, and Robson tools have ove...
Source: JEMS Patient Care - January 5, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives Patient Care EMS EMT Paramedic Prehospital Sepsis Source Type: news

Pages: 1  2